Chemed CORP

Chemed Corporation reported strong second-quarter 2026 financial results, with revenue up 8.8% and EPS soaring 43.7%, primarily driven by outperformance in its VITAS Healthcare segment, leading to an increase in full-year guidance.

Chemed Corporation's annual meeting saw the election of directors and ratification of independent accountants, but a non-binding vote on executive compensation failed to gain majority approval.

Chemed Corporation reported Q1 2026 results with strong VITAS growth, leading to an upward revision of full-year earnings guidance.

Chemed Corporation has successfully renewed its $450 million senior secured credit facilities, enhancing its financial flexibility with an expansion option.

Chemed Corporation reported a 9% drop in GAAP diluted EPS for Q4 2025, with its Roto-Rooter segment experiencing a significant revenue and EBITDA decline, while VITAS showed modest revenue growth.

Chemed Corporation reported a 3.1% revenue increase to $624.9 million for Q3 2025, but GAAP diluted EPS fell 10.8% to $4.46, driven by margin declines in both VITAS Healthcare and Roto-Rooter segments.

Chemed Corporation reported Q2 2026 results with an 8.8% increase in consolidated service revenues and sales, driven by strong performance in its VITAS hospice care segment.

Chemed Corporation's Q1 2026 filing reveals a 1.6% increase in consolidated revenue driven by VITAS, while Roto-Rooter experienced a slight decline, alongside significant stock repurchases.

Chemed Corporation reported a decline in net income and diluted EPS for Q3 and the first nine months of 2025, despite revenue growth, driven by increased operating expenses and a new cybersecurity incident at its VITAS segment.

Chemed Corporation experienced a decline in net income and EPS for Q2 2025 despite revenue growth, primarily due to a significant increase in Medicare Cap liability and higher casualty insurance expenses, alongside a notable executive departure.

Chemed Corporation's Q1 2025 shows revenue and earnings growth, fueled by VITAS Healthcare and Roto-Rooter.

Chemed Corporation's third-quarter results show strong growth in its VITAS hospice segment, which was partially offset by a decline in Roto-Rooter's revenue.

Chemed Corporation's 2025 annual report reveals a 12.2% drop in net income and a 7.7% decrease in diluted EPS, despite a 4.1% increase in consolidated service revenues, driven by higher Medicare cap liability and operational expenses.

Chemed Corporation files an amendment to its 2024 annual report to correct the number of securities available for future issuance under equity compensation plans.

Chemed Corporation's 2024 10-K filing highlights the company's financial performance, business segments, risk factors, and future outlook, with a focus on its VITAS and Roto-Rooter operations.

Chemed Corporation has filed its annual report on Form 10-K for the fiscal year ended December 31, 2023, detailing its financial performance and business activities.

Brian C Judkins, VP and Chief Legal Officer of Chemed Corp, reported multiple transactions in common stock on August 10, 2026.

Joel L Wherley, CEO - Vitas Healthcare of Chemed Corp, reported multiple transactions in common stock on August 5, 2026.

Kevin J Mcnamara, president and CEO and a Director of Chemed Corp, sold 2,000 shares of common stock on July 31, 2026 for $539.51 per share.

Patrick P Grace, a Director of Chemed Corp, sold 190 shares of common stock on July 31, 2026 for $532.00 per share.

Chemed Corp Director Andrea R. Lindell reported the acquisition of 1,347 shares of capital stock.

Director George J. Walsh III sold 500 shares of Chemed Corp common stock at a price of $437.83 per share.

Chemed Corporation has issued its 2026 proxy statement detailing the upcoming annual meeting, director elections, and executive compensation advisory vote.

Chemed Corporation's proxy statement outlines key proposals for the 2025 annual meeting, including director elections, executive compensation, and a stockholder proposal regarding special meetings.

Chemed Corporation's proxy statement details proposals for the upcoming annual meeting, including director elections, auditor ratification, executive compensation, and a shareholder proposal on golden parachutes.

AQR Capital Management, through its entities, now beneficially owns 7.25% of Chemed Corp's capital stock, reporting shared voting and dispositive power over a significant portion of these shares.

Vanguard Capital Management has disclosed beneficial ownership of 5.4% of Chemed Corp's common stock as of March 31, 2026.

Vanguard Portfolio Management has reported a beneficial ownership of 5.93% in Chemed Corp's common stock as of March 31, 2026.